This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Monday's Winners & Losers: Take-Two

Standard & Poor's said it would maintain its triple-A ratings on bond insurers Ambac (ABK) and MBIA (MBI).

Shares of Ambac were jumping 15.1% to $12.33, and MBIA was up 22.3% to $14.89.

Shares of video-games company Take-Two (TTWO) soared $9.53, or 54.9%, to $26.89 after its larger rival Electronic Arts (ERTS) made a $2-billion, or $26-a-share, unsolicited offer.

After Take-Two's management rejected the bid , EA turned hostile, taking its offer to Take-Two's shareholders. EA's stock fell $2.60, or 5.2%, to $47.14.

Shares of Genentech's (DNA) were climbing 8% after the FDA late Friday approved the use of Avastin in breast cancer. The accelerated approval was based on the benefits to progression-free survival -- the delayed growth of tumors -- when the drug is added to chemotherapy.

Avastin, currently a treatment for colorectal and non-small-cell lung cancers, is expected to receive full approval in breast cancer when the company submits data from two more studies. The approval came as something of a surprise, since an FDA panel voted 5-4 in December to recommend against the breast cancer approval.

Genentech shares were adding $6 to $77.60.

Heading in the opposite direction, small-cap Immtech Pharmaceuticals (IMM) plunged 45% after the company said it would discontinue the development program for pafuramidine, a late-stage investigational therapy for a type of pneumonia in AIDS patients. The action is in response to instances of abnormal kidney function, which resulted in hospitalization of several study participants.

Following the discontinuation of the study, Immtech won't receive further payments from Strativa, a division of Par Pharmaceuticals (PRX) that has commercialization rights to the drug candidate. Immtech shares tanked 90 cents to $1.10.

On the losing side was FirstFed Financial (FED), which fell 4% to $32.80 after the company increased its total nonperforming assets.

Meanwhile, Houston's Tesco (TESO), which creates technology solutions for the upstream energy industry, jumped 13.3% to $23.45 on fourth-quarter earnings. The company posted income of $6.6 million, or 18 cents a share, vs. $10.5 million, or 29 cents a share, in 2006. This year's fourth-quarter earnings include a $1.2 million loss related to expiration of its Turnkey E&P warrants. Analysts polled by Thomson Financial were looking for EPS of 17 cents, excluding items.

Shares of Marvell Technology (MRVL) gained 65 cents, or 5.9%, to $11.77 after a report in Barron's said the company could see its shares double in two years as its chips get integrated into new products.

Shares of ethanol company Verenium (VRNM) got pounded down 12.5% to $3.08 after the Cambridge, Mass., firm announced a $54 million convertible debt offering. Verenium is issuing senior convertible notes maturing April 1, 2012, and exchanging $16.7 million of these notes for $18.5 million of existing 5.5% convertible senior notes. The company said it was raising the money for general working capital purposes.

This article was written by a staff member of

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs